Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study Selmaj K, Kappos L, Arnold DL, Havrdova E, Boyko A, Kaufman M, Wiendl H, Rose J, Greenberg S, Demirhan E, et al. ACTRIMS-ECTRIMS 2014. 09/11/2014. CommentRecommendBookmarkWatch